Search
Cytosolic 10-formyltetrahydrofolate dehydrogenase
go.drugbank.com/bio_entities/BE0000933TargetHumansCytosolic 10-formyltetrahydrofolate dehydrogenase that catalyzes the NADP(+)-dependent conversion of 10-formyltetrahydrofolate to tetrahydrofolate and carbon dioxide (PubMed:19933275, PubMed:21238436).
Polypeptides: Cytosolic 10-formyltetrahydrofolate dehydrogenaseSynonyms: 10-FTHFDHBone morphogenetic protein 10
go.drugbank.com/bio_entities/BE0010910TargetHumansRequired for maintaining the proliferative activity of embryonic cardiomyocytes by preventing premature activation of the negative cell cycle regulator CDKN1C/p57KIP and maintaining the required expression levels of cardiogenic factors s...
Polypeptides: Bone morphogenetic protein 10Synonyms: BMP-10Bacillus calmette-guerin substrain russian BCG-I live antigen
go.drugbank.com/drugs/DB16648ApprovedInvestigationalIt was developed to alleviate Canada's multi-year shortage of BCG vaccine, and is expected to be available by mid-2021.[L32734] … [L32734] It is to be marketed by Verity Pharmaceuticals, under the trade name VERITY-BCG, and manufactured by the Serum Institute of India.
Tozuleristide
go.drugbank.com/drugs/DB15375InvestigationalTozuleristide is under investigation in clinical trial NCT02464332 (Safety Study of BLZ-100 in Adult Subjects With Sarcoma Undergoing Surgery).
Synonyms: N6.27-(6-(2-(7-(1,1-DIMETHYL-3-(4-SULFONATOBUTYL)-1H-BENZO(E)INDOL-1-IUM-2-YL)HEPTA-2,4,6-TRIENYLIDENE)-1,1-DIMETHYL-1,2-DIHYDRO-3H-BENZO(E)INDOL-3-YL)HEXANOYL)(15-ARGININE(K>R),23-ARGININE(K>R))CHLOROTOXINAfamelanotide
go.drugbank.com/drugs/DB04931Approved[L9092] Despite its relatively recent approval, afamelanotide has been available for use as an orphan drug in both the US and EU since 2008.[L9122,L9125] … [A187202,A187205] Afamelanotide is currently the only approved drug therapy used in the management of erythropoietic protoporphyria, having received approval in the EU in December 2014[L9119] and subsequent
Synonyms: MT-ISuccinic acid
go.drugbank.com/drugs/DB00139ApprovedInvestigationalNutraceutical(Hawley's Condensed Chemical Dictionary, 12th ed, p1099; McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed, p1851) … It is also used in foods as a sequestrant, buffer, and a neutralizing agent.
Mixtures: Se-Vate 21/7, Ferrex 150 PlusButalbital
go.drugbank.com/drugs/DB00241ApprovedIllicitDue to these risks, the use of butalbital-containing combination products is typically limited for use only in cases where other medications are deemed ineffective and such usage is advised to be carefully … There have not been clinical trials that evaluate the clinical efficacy of butalbital in migraines [A177754] thus it is not indicated for such condition.
Mixtures: Butalbital and Acetaminophen 50 mg/325 mg, Vtol LQConivaptan
go.drugbank.com/drugs/DB00872ApprovedIt was approved in 2004 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH).
Brexucabtagene autoleucel
go.drugbank.com/drugs/DB15699ApprovedInvestigational[L15148] Brexucabtagene autoleucel was granted full approval by the FDA on July 24, 2020 for the treatment of MCL and acute lymphoblastic leukemia (ALL), and is currently available through Kite Pharma … tumour cells in the CAR T cell preparation.
Categories: Receptors, Antigen, T-Cell, CD19-Directed Genetically Modified Autologous T-cell ImmunotherapiesMepenzolate
go.drugbank.com/drugs/DB04843ApprovedWithdrawnIt has not been shown to be effective in contributing to the healing of peptic ulcer, decreasing the rate of recurrence, or preventing complications. … Pharmacologically, it is a post-ganglionic parasympathetic inhibitor.